CD8A and melanoma: (28) demonstrated that the increase in CD8+ eomesodermin (EOMES)+ and CD8+ EOMES+granzyme B+ T cells, as well as the decline in CD4+ EOMES+Ki67+ T cells after ipilimumab, were associated with melanoma relapse.